Evaluation of Breast Conserving Surgery According to Molecular Subtypes in Kurdish Females


  • Shaban Latif Tofiq General Surgery Board Trainee Kurdistan Higher Council for Medical Specialties (KHCMS) and Sulaimani Teaching Hospital, Ministry of Health, Sulaimaniyah, Iraq.
  • Kamal Ahmad Saeed FIBMS (General Surgery), Professor, Department of Surgery, College of Medicine, University of Sulaimani, Sulaimaniyah, Iraq




Breast cancer, Breast-conserving surgery, Cross-sectional study, Margin involvement, Molecular subtype


Background & objectives:

 The most frequently occurring cancer in women is breast cancer, and various treatment methods are available. Thus, we aimed to correlate between molecular subtype and the suitability of performing breast-conserving surgery.                      

Methods: This retrospective cross-sectional study was conducted on 300 women with primary breast cancer, but without distant metastasis, from 2016 to 2022. These women had undergone either breast-conserving surgery or mastectomy. Patients were interviewed directly to obtain the necessary data, and their data were recorded on a questionnaire.

Results: The most common age group at diagnosis was 45-50 years, and the mean age for menarche was 13.3±1.3 years. Of the patients, 9% were single, 15% were nulliparous, and 76.7% had practised breastfeeding. The most common type of cancer was invasive ductal carcinoma, with ductal carcinoma in situ (82%). The molecular subtype and type of surgery were significantly correlated (p=0.041). Of the sample, 66.7% underwent breast-conserving surgery, with the highest rate (87%) being done in the triple-negative molecular subtype. Additionally, there was a significant correlation between the tumour focality and the postoperative margin (p<0.001).

Conclusions: Triple-negative cases were the most suitable for breast-conserving surgery among the molecular subtypes and had the highest rate of free margin. In contrast, unifocal breast cancers had the least involvement in margin postoperatively.


Download data is not yet available.


Mieog JS, Van Der Hage JA, Van De Velde CJ. Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Sys Rev 2007; (2): CD005002.

Salehiniya H, Ghoncheh M, Pournamdar Z. Incidence and Mortality and Epidemiology of Breast Cancer in the World. Asian Pacific J Cancer Prev 2016; 17(3): 43–6.

Yersal O, Barutca S. Biological subtypes of breast cancer: Prognostic and therapeutic implications. World J Clin Oncol. 2014; 5(3): 412-24.

Soliman NA, Yussif SM. Ki-67 as a prognostic marker according to breast cancer molecular subtype. Cancer Biol Med 2016; 13(4): 496-504.

Fragomeni SM, Sciallis A, Jeruss JS. Molecular subtypes and local-regional control of breast cancer. Surg Oncol Clin 2018; 27(1): 95-120.

Chen K, Li S, Li Q, , et al. Breast-conserving surgery rates in breast cancer patients with different molecular subtypes an observational study based on surveillance, epidemiology, and results (SEER) database. Med (Baltimore). 2016; 95(8): e2593.

Hassan AS, Somashekhar SP, Arun KN. Rate of Breast-Conserving Surgery vs Mastectomy in Breast Cancer: a Tertiary Care Centre Experience from South India. Indian J Surg Oncol. 2019; 10(1): 72–6.

Botteri E, Veronesi P, Vila J, et al. Improved prognosis of young patients with breast cancer undergoing breast-conserving surgery. Br J Surg 2017; 104(13): 1802–10.

Mazouni C, Naveau A, Kane A, et al. The role of Oncoplastic Breast Surgery in managing breast cancer treated with primary chemotherapy. Breast 2013; 22(6): 1189–93.

Manisha MY. A study on clinicopathological assessment of response to neoadjuvant chemotherapy in breast carcinoma. J Cancer Res Ther 2020; 16(6): 1419–25.

Soucy G, Bélanger J, Leblanc G, et al. Surgical Margins in Breast-Conservation Operations for Invasive Carcinoma: Does Neoadjuvant Chemotherapy Have an Impact? J Am Coll Surg 2008; 206(6): 1116–21.

Buchholz TA, Mittendorf EA, Hunt KK. Surgical Considerations After Neoadjuvant Chemotherapy: Breast Conservation Therapy Rationale and Randomized Trial Data. JNCI Monographs 2015; (51): 11-14.

Volders JH, Haloua MH, Krekel NMA, et al. Neoadjuvant chemotherapy in breast-conserving surgery – Consequences on margin status and excision volumes: A nationwide pathology study. Eur J Surg Oncol 2016; 42(7): 986–93.

Atkins J, Mushawah FA, Appleton CM, et al. Positive margin rates following breast-conserving surgery for stage I-III breast cancer: Palpable versus nonpalpable tumours. J Surg Res 2012; 177(1): 109–15.

Clough KB, Gouveia PF, Benyahi D, et al. Positive Margins After Oncoplastic Surgery for Breast Cancer. Ann Surg Oncol. 2015; 22(13): 4247–53.




How to Cite

Tofiq, S. L. ., & Saeed, K. A. . (2024). Evaluation of Breast Conserving Surgery According to Molecular Subtypes in Kurdish Females . AMJ (Advanced Medical Journal) , 9(2), 37-44. https://doi.org/10.56056/amj.2024.255